Fact checked by Nick Blackmer Eli Lilly’s Zepbound bested Novo Nordisk’s Wegovy in the first head-to-head trial comparing weight loss outcomes for people with obesity or overweight, according to top-line results shared by Lilly last week.

It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline access to the popular treatment.

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from drugmaker Eli Lilly.

Direct-to-consumer health and wellness company Ro will now offer access to lower-priced, single-dose vials of weight loss drug Zepbound through a new partnership with Eli Lilly. | Direct-to-consumer health and wellness company Ro will now offer access to lower-priced,

Ro partners with Eli Lilly to offer Zepbound, an FDA-approved obesity treatment, at affordable cash-pay prices through an integrated platform with home delivery.

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide, according to new data released Wednesday by Eli Lilly, the maker of Zepbound.